Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressing motor neuron disease that is characterised by selective loss of corticospinal neurons within the motor cortex and α-motor neurons of the spinal cord and brainstem (Bruijn et al., 2004) . The progressive loss of motor neurons results in atrophy of skeletal muscles and symptoms of muscle weakness, ultimately leading to paralysis and death due to the failure of respiratory muscles (Cozzolino et al., 2008) . The mechanisms leading to ALS are still unclear, but there is compelling evidence to suggest that neuroinflammation and innate immunity may contribute to the progression of disease (Lee et al., 2013) . The complement system has long been implicated in the pathogenesis of ALS, with numerous clinical and animal studies demonstrating strong up-regulation of complement activation fragments in the blood, skeletal muscle, cerebrospinal fluid and neurological tissue of ALS patients and similarly in animal models of ALS (Lee et al., 2012) .
One key factor produced following complement activation is the potent pro-inflammatory complement activation peptide C5a. C5a exerts its inflammatory effects through the GPCR C5a 1 receptor, also known as C5aR1, which is widely expressed on inflammatory cells such as granulocytes and monocytes/macrophages, as well as within the CNS, predominantly on glia (Woodruff et al., 2010) . Similar to other complement fragments, C5a 1 receptor is also dramatically up-regulated in ALS (Lee et al., 2012; Lee et al., 2013) . Given the role of C5a as a potent inflammatory mediator in other models of neurodegenerative diseases (Woodruff et al., 2006; Fonseca et al., 2009) , it has also become a potential therapeutic target for ALS. In support of this, we have previously demonstrated that therapeutic inhibition of C5a 1 receptor in hSOD1 G93A transgenic rats delays the onset of motor symptoms and increases survival compared with untreated animals (Woodruff et al., 2008) . Furthermore, we have shown that deletion of the C5ar1 gene increases survival in hSOD1 G93A mice (Woodruff et al., 2014) .
In the present study, we aimed to extend our earlier findings by examining the effect of C5a 1 receptor antagonism on disease progression in hSOD1 G93A mice, the most widely used preclinical model of ALS. We used the potent and selective, cyclic peptide C5a 1 receptor antagonist, PMX205, to therapeutically block C5a 1 receptors in hSOD1 G93A mice.
We found that orally administered PMX205 could enter the CNS at pharmacologically active concentrations and significantly improve hindlimb grip strength, slow disease progression and extend survival in hSOD1 G93A mice. These improvements were associated with reductions in proinflammatory (M1) monocytes and granulocytes and increased T-helper lymphocyte numbers in circulating blood. In summary, our results further validate the C5a-C5a 1 receptor signalling axis as a potential therapeutic target to slow disease progression in ALS.
Methods

Ethical statement
All experimental procedures were approved by the University of Queensland Animal Ethics Committee and complied with the policies and regulations regarding animal experimentation. They were conducted in accordance with the Queensland Government Animal Research Act 2001, associated Animal Care and Protection Regulations (2002 and , and the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 8th Edition. Animal studies are reported in compliance with the ARRIVE guideline (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
Animals
Transgenic hSOD1 G93A mice (B6-Cg-Tg (SOD1-G93A) 1Gur/J) expressing the high copy number (~25 copies) of mutant human SOD1 on a C57BL/6J background were initially obtained from The Jackson Laboratory (Bar Harbor, ME, USA). A breeding colony was maintained at the University of Queensland Biological Resources Animal Facilities under specific pathogen-free conditions. For all therapeutic efficacy studies, female hSOD1 G93A littermates were used and separated using a simple randomization procedure (coin toss) to receive either vehicle or drug treatment (i.e. litter-matched) in a double-blinded manner. Female hSOD1 G93A mice were used because of the higher availability of litter-matched controls of this gender; our prior studies in hSOD1 G93A x C5aR À/À mice indicate no gender difference in C5a 1 receptor-mediated disease pathology (Woodruff et al., 2014) . All animals were singly housed under identical conditions in a 12 h light/dark cycle (lights on at 0630 h) with free access to food and water.
Drug treatment
is an orally active cyclic hexapeptide that has been extensively described
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pharmacologically (March et al., 2004; Woodruff et al., 2005) . It was synthesized as previously described (Woodruff et al., 2005) and purified by reverse-phase HPLC. For early treatment, PMX205 was administered to mice via their drinking water (20 or 60 μg·mL À1 ). Based on drinking water measurements taken in hSOD1 G93A mice, these dosages equated to 3 and 9 mg·kg À1 ·day À1 respectively. Litter-matched female hSOD1 G93A transgenic mice were treated with PMX205 or distilled water alone (vehicle) from 35 days postnatal (termed 'pre-onset'). For late treatment, PMX205 or vehicle was administered from 91 days postnatal, which is approximately 21 days after initial motor deficit symptoms (termed 'post-onset'; Lee et al., 2013) . All drug treatments were continued daily throughout until the end-stage of disease (i.e. point of euthanasia). Prior to study commencement, a power analysis was performed on data obtained from previous hSOD1 G93A x C5aR1 À/À mice survival studies (Woodruff et al., 2014) , resulting in a sample size of n = 13 (power 80%, α 0.05, effect size 5%), which was used in the efficacy trials.
In the post-onset group, two mice from each group died during the trial due to non-ALS pathologies. According to the ALS preclinical guidelines (Ludolph et al., 2007; Scott et al., 2008) , the matched littermate was also removed from the trial, thus resulting in a final n = 9 for these groups. To avoid any potential bias, all drug and vehicle treatments were coded and then administered and subsequently analysed by a researcher (J.D.L.) blinded to the treatment groups. Decoding only occurred after each animal experiment was completed.
Disease progression and survival analysis
The rate of disease progression in hSOD1 G93A mice was determined by age at which maximal grip strength declined by 25, 50, 75 and 100%. Survival was determined by the inability of the animal to right itself within 15-30 s if laid on either side. This is a widely accepted end point for lifespan studies in ALS mice (Ludolph et al., 2007; Scott et al., 2008) and guarantees that the animal is killed before it is unable to reach food or water. Mice were killed by cervical dislocation following anaesthesia (i.p. injection of tiletamine 50 mg·kg À1 , zolazepam 50 mg·kg À1 and xylazine 12 mg·kg À1 ).
Weight measurements and hindlimb grip strength test
Vehicle-and PMX205-treated hSOD1 G93A mice were weighed weekly at the same time of day (1600 h), from 42 days of age until the defined end-stage (loss of righting reflex). A digital force gauge (Ugo Basile) was used to measure maximal hindlimb muscle grip strength as described previously (Lee et al., 2013) . Mice were held by their tail and lowered until their hindlimbs grasped the T-bar connected to the digital force gauge. The tail was then lowered until the body was horizontal with the apparatus, and the mice were pulled away from the T-bar with a smooth steady motion until both of their hindlimbs released the bar. The strength of the grip was measured in gram force. Each mouse was given 10 attempts and the maximum grip strength from these attempts recorded. The supernatant was removed after centrifugation and dried by vacuum concentration at room temperature. Samples were resuspended in 50 μL of 75% methanol/water, and 10 μL was analysed with an API 3200 triple quadrupole Q TRAP LC-MS/MS system with Turbo V ion source coupled with an Agilent 1200 series HPLC system. Chromatographic analysis was carried out with a Agilent Poroshell 120 SB-C18 analytical column (150 × 2.1 mm; 2.7 μm) under binary gradient conditions. For quantitative purposes, one m/z transition per analyte, that is, 420.32-70.0 for PMX205 and 448.86-120 for the internal standard PMX53, was monitored. PMX205 levels in the brain and spinal cord were expressed as ng·g À1 of tissue, with results corrected for process efficiency, extraction efficiency and recovery relative to the internal standard. The limit of detection for PMX205 using this method was 55 pg with an S/N ratio of 3.3.
BBB and BSB permeability assessments
For assessment of the blood-brain barrier (BBB) and blood-spinal cord barrier (BSB) permeability changes throughout disease progression, hSOD1 G93A and WT mice were injected with 100 μL of 10% sodium fluorescein via tail vein injection. After 15 min of injection, blood samples were collected via cardiac puncture for serum extraction. Mice were perfused with PBS followed by collection of the motor cortex and spinal cord. Samples were then homogenized in an equal volume of milliQ water followed by protein precipitation using acetonitrile. The supernatant of these samples was dried and reconstituted in equal weight volume of Tris buffer (pH 7.4). Fluorescence was determined in 10 μL of reconstituted samples analysed with 200 μL of Tris buffer (pH 7.4) using a plate reader with λ ex 460 nm and λ em 515 nm. Fluorescent uptake is the ratio of fluorescence in motor cortex and spinal cord relative to serum. Final results are expressed as relative fluorescence uptake in motor cortex and spinal cord samples of hSOD1 G93A mice compared with fluorescence uptake in WT controls.
Flow cytometry
Flow cytometry was performed to examine and quantify select immune cell populations in blood samples of vehicle-and PMX205-treated hSOD1 G93A mice at three stages of disease progression (onset, mid-symptomatic and end-stage) (Brennan et al., 2015) . In brief, mice were anaesthetized using methoxyflurane, and blood samples (100 μL) were collected through retro-orbital eye bleeds. The samples were diluted 1:4 with anticoagulant buffer (4 mM EDTA in 1 × PBS, pH 7.4) and subsequently lysed with red blood cell lysis buffer (0.85% NH 4 Cl in double distilled H 2 O, pH 7.4) for 5 min at room temperature. Following centrifugation at 500× g for 5 min at 4°C, the cells were resuspended in flow cytometry blocking buffer (0.5% BSA, 2 mM EDTA in 1 × PBS, pH 7.4) followed by incubation with rat anti-CD16/32 (1:200; BD Biosciences, North Ryde, NSW, Australia) for 10 min at 4°C to block F C receptors. Cells were immunolabelled with rat anti-Ly6G-BUV395 (1:100; BioLegend, San Diego, CA, USA), rat anti-Ly6C-V450 (1:200; BioLegend, San Diego, CA, USA), rat anti-CD3-Alexa488 (1:200; BD Biosciences, North Ryde, NSW, Australia), rat anti-CD4-BV786 (1:200; BioLegend, San Diego, CA, USA) and rat anti-CD11b-PE (1:300; BioLegend, San Diego, CA, USA) for 1 h at room temperature. All antibodies were diluted in the blocking buffer (0.5% BSA, 2 mM EDTA in 1 × PBS, pH 7.4). For the exclusion of dead cells, samples were also incubated with near-infrared conjugated viability dye Zombie NIR (1:100; BioLegend). Stained samples were then analysed using an LSR II flow cytometer (BD Biosciences) and FlowJo analysis software. After acquisition, compensation was applied to remove PE/Alexa 488 spectral overlap. Cell doublets and triplets were excluded based on FSC-A/FSC-H linearity. Gating strategies were applied as per Table 1 .
Data and statistical analysis
The data and statistical analysis in this study comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . All data are presented as mean ± SEM and all analyses were performed using GraphPad Prism 6.0 (San Diego, CA, USA). The statistical difference for survival analyses between vehicle-and PMX205-treated hSOD1 G93A mice was analysed using a log-rank (Mantel-Cox)
test. The statistical difference between vehicle-and PMX205-treated hSOD1 G93A mice for body weight, hindlimb grip strength and disease progression were analysed using a twoway ANOVA and a post hoc Fisher's least significant difference (LSD) test for each time point when F value for drug treatments was significant (P ≤ 0.05). For the results from flow cytometry, statistical difference between vehicle-and PMX205-treated hSOD1 G93A mice were also analysed using a two-way ANOVA and a post hoc Fisher's LSD test for each stages of disease progression. The statistical difference for levels of PMX205 and fluorescence uptake between WT and hSOD1 G93A mice was analysed using a two-tailed student t-test for each stage of disease progression. Differences between group means were considered significant when P ≤ 0.05.
Materials
PMX205 was synthesized and purified as described previously (Woodruff et al., 2005) . Tiletamine, zolazepam, xylazine were obtained from Lyppard Australia Pty Ltd, Melbourne, VIC, Australia.
Results
PMX205 concentrations in the brain and spinal cord of hSOD1 G93A mice correlate with BBB and BSB breakdown
We have previously shown the C5a 1 receptor to be progressively up-regulated on reactive microglia in hSOD1 G93A mice (Lee et al., 2013) . Here, we used a validated quantitative LC-MS/MS method to assess entry of the selective C5a 1 receptor antagonist PMX205 into the brain and spinal cord at various stages of the disease progression. Plasma PMX205 levels were similar in WT and hSOD1 G93A mice and did not alter throughout disease progression ( Figure 1A ). By contrast, the levels of PMX205 progressively increased in the brain and spinal cord of hSOD1 G93A mice, reaching threefold to fourfold (brain) and threefold to fivefold (spinal cord) that of age-matched WT mice ( Figure 1B, C) . Interestingly, PMX205 levels in the brain were increased very early in the disease ( Figure 1B) , suggesting an early disruption of the BBB in these mice. To investigate if the increased penetration of PMX205 in hSOD1 G93A brains and spinal cords during disease correlated with progressive breakdown of the BBB or BSB, we used fluorescein uptake as a measure of barrier permeability. We observed a progressively increasing uptake of fluorescein in the motor cortex and lumbar spinal cord with disease in hSOD1 G93A mice, compared with WT mice (Figure 1D , E).
The temporal pattern of fluorescein uptake mirrored that of PMX205 brain and spinal cord levels ( Figures 1B, C) , collectively suggesting that increased entry of PMX205 in the brain and spinal cord of hSOD1 G93A mice indeed correlated with increased BBB and BSB permeability. Finally, we aimed to identify whether our proposed therapeutic dosing regimen (i.e. oral drinking water PMX205 administration) could result in therapeutically active levels of PMX205 in the CNS tissues of hSOD1 G93A mice. We thus allowed ) ad libitum over a period of 5 days. Using this dosage regime, we found that PMX205 could effectively enter the brain and spinal cord at levels substantially above the expected IC 50 for C5a 1 receptor inhibition (March et al., 2004; Woodruff et al., 2005) . Furthermore, similar to our i.v. dosing studies, we identified increased levels of PMX205 in the CNS of hSOD1 G93A mice compared with WT mice ( Figure 1F ). Together, this demonstrates that oral dosing of PMX205 in the drinking water at 60 μg·mL À1 is able to reach the CNS at therapeutically relevant concentrations, and this route and dose of administration were thus used in our follow-up studies on efficacy.
C5a 1 receptor antagonist PMX205 treatment extends survival, improves hindlimb grip strength and slows disease progression in hSOD1 G93A mice
In this first efficacy study, a cohort of litter-matched hSOD1 G93A mice were treated with PMX205 or vehicle from 35 days of age onwards. PMX205 treatment at 60 μg·mL
À1
in the drinking water resulted in an average dose of 9 mg·kg À1 ·day À1 based on drinking volume measurements throughout the study (3-4 mL·day À1 ). hSOD1 G93A mice treated with PMX205 from this 'pre-onset' age had a significant extension in survival time when compared with littermatched untreated hSOD1 G93A mice (Figure 2A ). The weight of vehicle-and PMX205-treated hSOD1 G93A mice both reached the maximum at 126 days of age; however, there was no difference in body weight loss between vehicleand PMX205-treated hSOD1 G93A mice ( Figure 2B ). Motor deficits were also assessed in these animals using hindlimb grip strength, a sensitive marker of neuromotor performance (Lee et al., 2013) . PMX205 treatment significantly counteracted the loss of hindlimb grip strength from 105 days of age ( Figure 2C) found that PMX205 treatment at this dose also significantly slowed disease course, delaying the progressive loss of motor function ( Figure 2D ).
Post-onset PMX205 treatment extends survival and slows disease progression but does not significantly impact motor performance in hSOD1 G93A mice
We next determined if inhibition of C5a 1 receptors at a later stage of disease could still reduce ALS pathology in mice. This is particularly important as ALS patients generally present in the clinic with manifest disease, where motor neuron loss has already progressed. Thus, this experiment provides a model that would more closely follow a therapeutic intervention for human ALS patients. hSOD1 G93A mice were therefore orally dosed with PMX205 (9 mg·kg À1 ·day À1 ) at 91 days of age, when there is already considerable decline in motor performance and motor neuron loss in the hSOD1 G93A mouse model (Lee et al., 2013) . Importantly, PMX205 treatment in hSOD1 G93A mice from this post-onset disease age also resulted in an increase in survival time compared with littermatched vehicle-treated hSOD1 G93A mice ( Figure 3A ). Similar to the pre-onset treatment group, post-onset PMX205 treatment did not affect body weight loss in hSOD1 G93A mice ( Figure 3B ). Post-onset PMX205 treatment also did not significantly improve grip strength loss in hSOD1 G93A mice ( Figure 3C ). Importantly, however, post-onset PMX205 treatment significantly slowed disease progression at the later stages of disease, with delays to the loss of maximal grip strength ( Figure 3D ). This demonstrates that treatment of ALS mice with PMX205, well into their disease progression, can still have therapeutic benefits, albeit to a lesser degree than the earlier treatment regimen. and an inability to right itself once placed on its back (n = 9). *P < 0.05, significantly different from vehicle; log-rank test). (A, right panel) The end-stage survival age for each litter-matched pair of vehicle-and PMX205-treated hSOD1 G93A mice. (B, C) Body weight and hindlimb grip strength in vehicle-and PMX205-treated hSOD1 G93A mice (n = 9). *P > 0.05, significantly different from vehicle; two-way ANOVA. (D) Disease progression (determined by age at which maximal grip strength decline at 25, 50, 75 and 100%) in hSOD1 G93A mice treated with vehicle or PMX205 (n = 9). *P < 0.05, significantly different from vehicle, two-way ANOVA with Fisher's LSD test at each quartile. Data are expressed as mean ± SEM.
PMX205 treatment reduces circulating blood
C5a 1 receptor antagonism is protective in ALS mice BJP mice ( Figure 4D ). Interestingly, eosinophil granulocyte (CD11b + Ly6G + Ly6C + SSC hi ) numbers were initially increased in PMX205-treated hSOD1 G93A mice at onset stage but then significantly decreased at the mid-symptomatic stage compared with vehicle-treated hSOD1 G93A mice ( Figure 4E ). By contrast to monocytes and granulocytes, helper T-cell (CD3 + CD4 + ) numbers were increased at endstage disease ( Figure 4F ). Non-helper/cytotoxic T-cell (CD3 + CD4 À ) numbers were significantly decreased at the mid-symptomatic stage compared with vehicle-treated hSOD1 G93A mice ( Figure 4G ). Overall, these flow cytometry studies indicate a reduced pro-inflammatory leukocyte phenotype in the blood of hSOD1 G93A mice treated with PMX205 at mid-symptomatic stage of disease.
Discussion
Currently, there is no effective treatment for ALS. Although the pathogenesis of ALS is still unclear, there is convincing evidence that inflammation, both peripheral and central, may contribute substantially to disease. The complement system is emerging as a potential key innate immune system that is activated in multiple neurological diseases, promoting neuroinflammation and disease progression (Brennan et al., 2016) . Previous studies have demonstrated that several complement factors, including C1q, factor B, C3, C4 and C5a 1 receptors, are significantly increased during ALS progression in hSOD1 G93A mice (Lee et al., 2013) . However, genetic deletion of C1q, C3 and C4 in hSOD1 transgenic mouse models has not shown any significant beneficial effects on disease progression (Chiu et al., 2009; Lobsiger et al., 2013) , although it should be noted that this strategy does not eliminate direct activation of C5 via the extrinsic pathway (Huber-Lang et al., 2006) . Consistent with this, our prior studies showed that genetic deletion of C5a 1 receptors in hSOD1 G93A mice extends survival (Woodruff et al., 2014) . In addition, we also previously showed that chronic administration of C5a 1 receptor antagonists to hSOD1 G93A transgenic rats delayed the onset of motor symptoms and increased survival compared with untreated diseased animals (Woodruff et al., 2008) . Collectively, these findings show that complement effector mechanisms downstream of C5 do contribute to disease progression and need to be directly targeted. In the present study, we have extended our previous work by conducting a detailed assessment of PMX205 pharmacokinetics with disease progression and by testing the benefits of pharmacological C5a 1 receptor inhibition before and after disease onset in hSOD1 G93A mice, the most commonly used preclinical model of ALS.
Figure 4
Circulating blood monocytes, granulocytes and T lymphocytes in vehicle-and PMX205-treated hSOD1 G93A mice. hSOD1 G93A mice were orally dosed with the selective C5a 1 receptor antagonist PMX205 at 35 days of age (9 mg·kg À1 ·day À1 in drinking water through to end-stage Figure S1 ), indicating a dose-dependency of the beneficial effects of PMX205. A similar dose-dependency has been observed in a transgenic mouse model of Alzheimer's disease where a dose of 3 mg·kg À1 ·day À1 was found ineffective but an oral drinking water dose equivalent to 6 mg·kg À1 ·day À1 did achieve efficacy (Jain et al., 2013) . Furthermore, a recent study demonstrated that an 8 mg·kg À1 ·day À1 oral dose of PMX205 was required to achieve efficacy in a mouse model of inflammatory bowel disease, while a 4 mg·kg À1 ·day À1 dose showed no effect (Jain et al., 2013) . These findings underline the importance of optimal dose selection for PMX205, which may explain the lack of efficacy at lower doses of PMX205, as reported by others (Klos et al., 2013) . Drug treatment experiments included hSOD1 G93A mice dosed from a very early age (day 35) to determine the maximum effect of C5a 1 receptor blockade, as well as at a later time point, clearly after the onset of motor deficits (day 91). Our results showed that there was no significant difference in survival time extension between the two dosing groups, suggesting that the pathogenic involvement of C5a was more likely to occur subsequent to day 91 in this model. This is in agreement with our previous finding that up-regulation of C5a 1 receptors occurs late in the disease course, that is, at 130 and 175 days in hSOD1 G93A mice (Lee et al., 2013) . These results also indicate that C5a-C5a 1 receptor signalling exacerbates disease pathology but does not trigger the onset of disease. It should be noted, however, that CNS uptake of PMX205 also increases with disease progression (Figure 1 ) and that this in turn may account for the similar survival efficacy between pre-and post-onset groups. Although there was no difference in the increased survival time between pre-and post-onset treatments, initiation of PMX205 treatment after disease onset did not significantly improve hindlimb grip strength. These findings are consistent with the fact that the onset of motor deficits, as measured by hindlimb grip strength, is closely correlated with the decline in lumbar spinal cord motor neuron numbers, which normally occurs prior to 70 days in hSOD1 G93A mice (Lee et al., 2013) . Hence, treating these animals at day 91 when there is already significant decline in motor neuron numbers would only be expected to show minimal improvement in neuromotor function. Post-onset PMX205 treatment did, however, still have a benefit by delaying the age at which hSOD1 G93A mice reached 75%
and 100% decline in their maximal grip strength (i.e. mice did have a slower disease progression). Our studies also demonstrated that there is an early disruption of BBB and BSB permeability in hSOD1 G93A mice based on fluorescein extravasation. These findings support previous studies demonstrating damage to BBB and BSB integrity in hSOD1 G93A mice via ultrastructural capillary alterations and leakage in the lumber spinal cord at both early and late stages of disease (Garbuzova-Davis et al., 2007a,b; Zhong et al., 2008) . Collectively, these findings suggest that there are functional impairments in barrier integrity very early in disease, potentially preceding significant motor neuron death (Zhong et al., 2008) . Interestingly, the progressive increase in barrier permeability in hSOD1 G93A mice during the disease course mirrored the increase in PMX205 levels in the brain and spinal cord. This has clear implications for any potential future clinical trials using PMX205, as there may be enhanced uptake of this drug by target tissues (i.e. motor cortex and spinal cord) that are undergoing degeneration in ALS with disease progression. Another interesting finding from this study was the demonstration of higher CNS tissue distribution of PMX205 following oral drinking water dosing compared with i.v. dosing where much higher blood concentrations were observed. Prior studies have demonstrated that this class of molecules are relatively lipophilic and display rapid tissue distribution following dosing (Woodruff et al., 2005) . PMX205 also has a relatively low oral bioavailability (Woodruff et al., 2005) , which is in line with the low blood levels observed following oral dosing in this study. It is possible that there was slower elimination of PMX205 from the CNS compared with the blood circulation, resulting in increased levels of drug observed within the CNS over the 5-day dosing period. Importantly, as this class of C5a 1 receptor antagonists are insurmountable antagonists with an extremely low off-rate, they effectively act as pseudoirreversible inhibitors of C5a-C5a 1 receptor signalling (Paczkowski et al., 1999) . Therefore, despite low circulating blood levels following drinking water dosing, widespread and prolonged blockade of C5a 1 receptors would still be expected (Seow et al., 2016) . Additional studies are warranted to further explore the nature of PMX205 pharmacokinetics and pharmacodynamics in CNS disease and how this can potentially be modified to improve therapeutic outcomes.
In addition to microglia activation, it is now also well accepted that peripheral immune cells, including monocytes and T lymphocytes, can modulate motor neuron death in ALS animal models (Beers et al., 2008; Butovsky et al., 2012) . In our study, we found that there was a significant reduction in pro-inflammatory M1 monocyte numbers in the blood of PMX205-treated hSOD1 G93A mice at midsymptomatic stage of disease compared with untreated mice. This supports studies demonstrating that disease progression and neuronal damage can be attenuated in hSOD1 G93A mice by depleting Ly6C-positive monocytes (Butovsky et al., 2012) . We also found that blockade of C5a 1 receptors in hSOD1 G93A mice decreased circulating CD4 À T lymphocytes, while the number of CD4 + T lymphocytes increased. These findings suggest an overall dampening of the inflammatory response with disease progression, which are also consistent with previous reports showing that helper and regulatory T lymphocytes are neuroprotective, whilst cytotoxic T lymphocytes are pathogenic in hSOD1 G93A mice (Beers et al., 2008) . Finally, we observed that there was a significant decrease in neutrophil and eosinophil granulocyte numbers in PMX205-treated hSOD1 G93A mice at mid-stage of disease.
The role of granulocytes in the disease progression of ALS is not well studied, although recent data suggest these cell types may play active roles in neurodegenerative disease (Zenaro et al., 2015) . Additional research, including examining the effects of PMX205 on neuropathology and immune cell infiltration into the CNS, is thus warranted to further explore the mechanisms of PMX205 neuroprotection in SOD1 G93A mice.
In summary, the present study demonstrates for the first time that oral administration of the selective and CNSpermeable C5a 1 receptor antagonist, PMX205, both preand post-onset, can significantly attenuate disease in hSOD1 G93A mice. In the blood, pro-inflammatory M1 monocytes, granulocytes and CD4 À T lymphocyte numbers were all decreased at mid-stage of disease, while the number of CD4 + helper T lymphocytes was increased following PMX205 treatment. Together, these findings indicate that blockade of C5a 1 receptors significantly attenuates hSOD1 G93A disease progression and associated inflammation, which in turn transiently affects the number of circulating pro-inflammatory leukocytes. Whether this effect on immune cells in the blood is the cause or consequence of PMX205 efficacy is currently under investigation. Overall, our studies affirm the view that blocking the C5a 1 receptor, the receptor for the C5 activation fragment, C5a, is a useful therapeutic strategy to modify disease course in ALS.
